Form 4: Arrowhead Pharmaceuticals Director Equity Grant

Director Matthew Gregory Cohen received a grant of 11,882 restricted stock units from Arrowhead Pharmaceuticals.

Summary

• Director Matthew Gregory Cohen was granted 11,882 restricted stock units (RSUs) on June 15, 2026.
• The grant represents equity compensation for the director.
• The RSUs are subject to a three-year vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor dilution to existing shareholders upon the eventual vesting and issuance of the underlying common stock.

Risks

• None identified in this specific filing.

Future Outlook

The RSUs will vest over a three-year period, indicating a long-term commitment by the director to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director equity is consistent with standard governance practices for NASDAQ-listed pharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders.

Next Steps

• Vesting of the restricted stock units over the next three years.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Form 4, Insider Trading, Equity Compensation, Director Stock Grant